Phase I testing of hu14.18-IL2 in pediatric patients with recurrent or refractory neuroblastoma demonstrated biologic activity and clinical tolerability when administered at a MTD of 12 mg/m2/day on days 1-3 of a 28-day cycle. Here, IL2 is linked to neuroblastoma.